World

KANSAS CITY, Kan., Nov. 10, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products, announced

Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating mean weight

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointment

Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT) Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping

After years of pulling back, carriers are spending to win homeowners again, returning to storm- and fire-hit markets within months, and following regulatory change into new states LOS ANGELES, Nov. 10, 2026

Substantial progress has been made in advancing production capabilities BOCA RATON, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTCQB: XERI), a company dedicated to the discovery, development, and commercialization of

CHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced

CXU™ formula already evaluated with human collagen in the 12-month P.R.O.O.F.™ preclinical study; first pilot batch of Conexeu’s own human collagen met predefined Company specifications Highlights Conexeu has launched a human collagen